Overview of (invented) names reviewed in September 2026 by the Name Review Group (NRG) - Adopted at the CHMP meeting of 15 October 2026
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026
Human medicines European public assessment report (EPAR): Fovlussea, ranibizumab, Ophthalmologicals, Status: Opinion
Human medicines European public assessment report (EPAR): Neuzafy, filgrastim, Status: Opinion
Human medicines European public assessment report (EPAR): Foundayo, Orforglipron, Status: Opinion
Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Opinion
Human medicines European public assessment report (EPAR): Yuviwel, Navepegritide, Status: Opinion
Summary of opinion: Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune), 15/10/2026 Positive
Summary of opinion: Talvey, 15/10/2026 Positive
Summary of opinion: Tukysa, 15/10/2026 Positive